Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v3-EN Version v2-FR
Language English French
Date Updated 2020-07-30 2020-07-22
Drug Identification Number 02474433 02474433
Brand name OGIVRI OGIVRI
Common or Proper name TRASTUZUMAB TRASTUZUMAB
Company Name BIOSIMILAR COLLABORATIONS IRELAND LIMITED BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Ingredients TRASTUZUMAB WATER TRASTUZUMAB WATER
Strength(s) 440MG 20ML 440MG 20ML
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 1VL TRASTUZUMAB 1VL BWFI 1VL TRASTUZUMAB 1VL BWFI
ATC code L01XC L01XC
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date
Actual start date 2020-07-17 2020-07-17
Estimated end date 2020-08-04 2020-08-04
Actual end date 2020-07-30
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Limited product supply is available on allocation Limited product supply is available on allocation
Health Canada comments